Ibrutinib
Generic Details
Generic Name
Ibrutinib
Other Names
- Imbruvica
Drug Class
- Kinase Inhibitor
Chemical Formula
C25H24N6O2
Molecular Weight
440.5 g/mol
Mechanism of Action
- Irreversible inhibition of Bruton's tyrosine kinase (BTK)
Indications
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
- Waldenström's macroglobulinemia
- Marginal zone lymphoma
Common Dosage Forms
- Capsules
Typical Dosage
- 420 mg once daily
Pediatric Dosage
- Not established
Geriatric Dosage
- Dose adjustment may be needed in elderly patients
Side Effects
- Nausea
- Diarrhea
- Fatigue
- Muscle pain
- Bruising
- Risk of bleeding
Contraindications
- Hypersensitivity to ibrutinib
Pregnancy Category
- C - use with caution
Lactation Safety
- Not recommended
Drug Interactions
- Strong CYP3A4 inhibitors/inducers
- Anticoagulants
Overdose Symptoms
- Increased risk of bleeding
Antidote for Overdose
- Supportive care
Storage Conditions
- Store at room temperature (20-25°C)
Pharmacokinetics
- Absorption: Rapid and high bioavailability
- Distribution: Extensively bound to plasma proteins
- Metabolism: Primarily hepatic via CYP3A4
- Excretion: Mainly feces
Precautions
- Monitoring for bleeding events
- Regular liver function tests
Warnings
- Increased risk of infections